Literature DB >> 24964960

MDM2 SNP309 and risk of endometrial cancer.

Stian Knappskog1, Per Eystein Lønning.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24964960     DOI： 10.1007/s13277-014-2244-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


× No keyword cloud information.
  8 in total

1.  SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.

Authors:  Stian Knappskog; Jone Trovik; Janusz Marcickiewicz; Solveig Tingulstad; Annetine C Staff; Pål Romundstad; Kristian Hveem; Lars Vatten; Helga B Salvesen; Per E Lønning
Journal:  Eur J Cancer       Date:  2011-11-24       Impact factor: 9.162

2.  Common variant on MDM2 contributes to endometrial cancer susceptibility: evidence based on 7 studies.

Authors:  Yan Zhao; Xiaoer Yang; Xiaojiao Hao; Xiaolin Pan; Bo Zhao; Jingwen Ma; Jian Fang; Minghong Zhao
Journal:  Tumour Biol       Date:  2014-05-03

3.  The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.

Authors:  Stian Knappskog; Merete Bjørnslett; Line M Myklebust; Petra E A Huijts; Maaike P Vreeswijk; Hege Edvardsen; Yongli Guo; Xuemei Zhang; Ming Yang; Sanna K Ylisaukko-Oja; Pia Alhopuro; Johanna Arola; Rob A E M Tollenaar; Christi J van Asperen; Caroline Seynaeve; Vidar Staalesen; Ranjan Chrisanthar; Erik Løkkevik; Helga B Salvesen; D Gareth Evans; William G Newman; Dongxin Lin; Lauri A Aaltonen; Anne-Lise Børresen-Dale; Grethe S Tell; Camilla Stoltenberg; Pål Romundstad; Kristian Hveem; Johan R Lillehaug; Lars Vatten; Peter Devilee; Anne Dørum; Per E Lønning
Journal:  Cancer Cell       Date:  2011-02-15       Impact factor: 31.743

4.  A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

Authors:  Gareth L Bond; Wenwei Hu; Elisabeth E Bond; Harlan Robins; Stuart G Lutzker; Nicoleta C Arva; Jill Bargonetti; Frank Bartel; Helge Taubert; Peter Wuerl; Kenan Onel; Linwah Yip; Shih-Jen Hwang; Louise C Strong; Guillermina Lozano; Arnold J Levine
Journal:  Cell       Date:  2004-11-24       Impact factor: 41.582

5.  DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.

Authors:  D-W Wu; M-C Lee; J Wang; C-Y Chen; Y-W Cheng; H Lee
Journal:  Oncogene       Date:  2013-04-15       Impact factor: 9.867

6.  MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk.

Authors:  Stian Knappskog; Per E Lønning
Journal:  Oncotarget       Date:  2011-03

7.  Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649).

Authors:  Stian Knappskog; Liv B Gansmo; Khadizha Dibirova; Andres Metspalu; Cezary Cybulski; Paolo Peterlongo; Lauri Aaltonen; Lars Vatten; Pål Romundstad; Kristian Hveem; Peter Devilee; Gareth D Evans; Dongxin Lin; Guy Van Camp; Vangelis G Manolopoulos; Ana Osorio; Lili Milani; Tayfun Ozcelik; Pierre Zalloua; Francis Mouzaya; Elena Bliznetz; Elena Balanovska; Elvira Pocheshkova; Vaidutis Kučinskas; Lubov Atramentova; Pagbajabyn Nymadawa; Konstantin Titov; Maria Lavryashina; Yuldash Yusupov; Natalia Bogdanova; Sergey Koshel; Jorge Zamora; David C Wedge; Deborah Charlesworth; Thilo Dörk; Oleg Balanovsky; Per E Lønning
Journal:  Oncotarget       Date:  2014-09-30

8.  MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis.

Authors:  Qiliu Peng; Cuiju Mo; Aiping Qin; Xianjun Lao; Zhiping Chen; Jingzhe Sui; Junrong Wu; Limin Zhai; Shi Yang; Xue Qin; Shan Li
Journal:  J Exp Clin Cancer Res       Date:  2013-11-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.